Clinical Trial Update: Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating lenalidomide in combination with modified DA-EPOCH and rituximab (EPOCH-R2) for primary effusion lymphoma and KSHV-associate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Effusion Lymphoma
• Kshv-associated Large B-cell Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Cytoxan (cyclophosphamide)
• Deltasone (prednisone)
• Oncovin (vincristine)
• Revlimid (lenalidomide)
• Rituxan (rituximab)
• VePesid (etoposide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Effusion Lymphoma, B-Cell Neoplasm | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-28